Modern treatment of acute lymphoblastic leukaemia (ALL) in childhood results in successful clinical and haematological remission in most children. If this is followed by central nervous system prophylaxis and combination maintenance chemotherapy, a diseasefree survival rate of up to 50% at 5 years can be expected.1 Although the optimum length of maintenance chemotherapy is not certain,2 it is probably between 2 and 3 years.
Most protocols, including those of the UK ALL trials of the Medical Research Council, include routine bone marrow examination during maintenance therapy. In the UK ALL trials, bone marrow examinations are performed at 3-monthly intervals, timed to coincide with the start of each 12-week module in the maintenance schedules.
We realised that most marrow examinations carried out during maintenance therapy showed no evidence of leukaemia, and decided to find out how many marrow relapses were detected by routine marrow examinations. Patients A 'normal' peripheral blood count was defined in this study as one in which all values were equal to, or 392 greater than, the following: haemoglobin 10 5 g/dl, white cell count 2 5 x 109/l, platelet count 120 x 109/l. These values were chosen to take account of the cytopenia induced by maintenance therapy.
In this unit, the blood count is performed on a capillary sample and the result, including a differential white cell count, is obtained before the child is seen by the clinician. It was therefore possible to detect any child who had developed any haematological change, including circulating blast cells, since his last attendance.
A non-routine marrow examination was defined as one performed for any of the following reasons: circulating blast cells, bone pain, uncertain morphology, or an abnormal count without blast cells if relapse was suspected.
Most of the routine marrow examinations were carried out under a short halothane/oxygen/nitrous oxide anaesthetic, although many of the non-routine marrow examinations were performed under local anaesthesia.
Results
Five hundred and fifty-seven routine marrow examinations were performed (Table 1) , only 9 (1-6 %) showed relapse. These may be considered as unexpected relapses and it is significant that only 2 of these children had normal blood counts at the time of their marrow examination. The other 7 relapses showed varying degrees of cytopenia, but no circulating blast cells.
Forty-five (8 %) of the routine marrow examinations were performed on children with peripheral blood counts at the time of marrow examination showing one, or more, haemoglobin value, white count, or platelet count below the 'normal' values used in this study. This cytopenia was considered to be a result of marrow depression by chemotherapy and none of these marrow examinations showed evidence of leukaemia.
Fourteen non-routine marrow examinations were performed (Table 2) , only 3 failed to confirm marrow relapse. Two were performed because of pronounced peripheral blood cytopenia which was shown to be the result of drug-induced marrow depression. The third examination was performed because, although The analysis showed that 20 (3 * 5 %) marrow relapses were detected out of 571 marrow examinations and 11 were found by non-routine marrow examination, generally as a result of finding circulating blast cells. The remaining 9 relapses were found on routine examinations. Six of these had abnormal counts with no blast cells, but a comparison of the actual values with those of the 45 (8%) marrow examinations who, by chance, had abnormal counts at the time of the routine marrow examination, unfortunately showed that the children in relapse could not be distinguished with certainly from those whose marrows did not show leukaemic infiltration. It was however, noted that platelet counts <100 x 109/l were more common, 50% (3 of 6) in those children who had indeed relapsed compared with 24 % (1 1 of 45) in those with abnormal counts, but no evidence of relapse in the marrow. Only 2 children with 'normal' counts were shown on marrow examination to have relapsed, whereas 503 marrow examinations in children with 'normal' blood counts were performed to confirm the absence of relapse.
Discussion
The incidence of unexpected relapse on routine biopsy in children with 'normal' counts was 0 4%. If only children with abnormal counts, without circulating blasts, were to have routine marrow examinations performed the incidence of relapse would be 12% (6 in 52) which represents a 30-fold increase. However, this still means that about 9 out of every 10 such marrow examinations would not show relapse. If it could be shown that detection of marrow relapse before circulating blast cells are seen would result in a better reinduction rate or longer second remission, one could perhaps argue more strongly that routine marrow examination was valuable. In this small series of 20 relapses (11 detected by non-routine marrow examination, 9 by routine examination), 8 children in the first group and 6 in the second group achieved a second remission.
Because of the small number of patients no useful comment can be made about the duration of the second remission. However, in view ofthe overall poor prognosis of children with ALL who have bone marrow relapses during treatment,4 or after treatment has stopped,5 it seems improbable that overall survival after relapse would be much, if at all, reduced by the abolition of routine marrow examinations. It should be stressed that each child in this study, by the design of the study, had had a normal marrow examination at least 12 weeks before.
The figures presented in this study show that routine marrow examination every 3 months in children with ALL or NHL has a low (0 4%) relapse yield if the peripheral count is normal; even if the count is abnormal, without circulating blast cells, the yield only increases to a modest 12 %.
It is therefore suggested that routine marrow examination during maintenance therapy is not worth while and should not be included in the protocols of future studies. The clinician must obviously establish remission in a new case after induction therapy and should not hesitate to proceed to marrow examination in a child in remission whose peripheral counts indicate cause for concern.
It is hoped that the well-known trauma to child, parents, and doctor of performing a marrow examination in a conscious or poorly-sedated child will be lessened by the abolition of routine marrow examination. In addition the small, but ever present, risk of a general anaesthetic in those units fortunate enough to have such a service, will be lessened even further by the administration of fewer anaesthetics. We thank Mrs M Coggin for secretarial assistance, and Staff Nurse J Young for help with the data extraction.
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Congenital villous atrophy associated with stagnant loop syndrome J F B DOSSETOR Department of Child Health, Royal Hospital for Sick Children, Glasgow SUMMARY A child who presented at age 9 months with steatorrhoea and malnutrition is described. After an initial period of intravenous feeding it was found that oral gentamicin led to a reduction of clinical steatorrhoea and an increase in weight, and so gentamicin was continued for 18 months. Investigation showed severe villous atrophy without pronounced inflammatory cell infiltrate and with no increase in intraepithelial lymphocytes. The villous atrophy was not present in the duodenum but started in the jejunum. The small-intestine was radiologically dilated throughout its length. It is suggested that this structurally-abnormal gut acted as a stagnant loop and exacerbated the steatorrhoea. 
